Literature DB >> 7661883

HDL, its enzymes and its potential to influence lipid peroxidation.

M I Mackness1, P N Durrington.   

Abstract

In seeking an explanation of the inverse relationship between serum high density lipoprotein (HDL) concentration and coronary heart disease (CHD) incidence, most investigations have been directed at its role in reverse cholesterol transport. However, recently it has become clear that HDL has the potential to limit oxidative modification of low density lipoprotein (LDL) whether induced by transition metals or by cells in tissue culture. In view of the current theory that oxidative modification of LDL is an important element in atherogenesis, this suggests another potential mechanism by which HDL might impede the development of CHD. HDL is the major carrier of cholesteryl ester hydroperoxides, but more than this it appears to have the prolonged capacity to decrease the total amount of lipid peroxides generated on LDL during oxidation while the quantity accumulating on HDL itself reaches an early plateau. These effects are not explained by chain-breaking antioxidants present in HDL and are likely to involve an enzymic mechanism. Several enzymes are present on HDL: paraoxonase, lecithin:cholesterol acyl transferase, platelet activating factor acetylhydrolase, phospholipase D and protease. Apolipoproteins, such as apolipoprotein AI, could also have enzymic activity. Evidence that some of these might act to metabolise lipid peroxidation products, such as oxidised phospholipids and lyso-phosphatidylcholine, is discussed in this review.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7661883     DOI: 10.1016/0021-9150(94)05524-m

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  55 in total

1.  Oxidative modification and poor protective activity of HDL on LDL oxidation in thalassemia.

Authors:  Supeenun Unchern; Narumon Laohareungpanya; Yupin Sanvarinda; Kovit Pattanapanyasat; Pansakorn Tanratana; Udom Chantharaksri; Nathawut Sibmooh
Journal:  Lipids       Date:  2010-06-09       Impact factor: 1.880

2.  Serum paraoxonase levels in patients with acute liver disease.

Authors:  C M Bindu; Usha Anand; C V Anand
Journal:  Indian J Clin Biochem       Date:  2011-01-12

Review 3.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects.

Authors:  Soudabeh Fallah; Morteza Seifi; Asghar Ghasemi; Mohsen Firoozrai; Ali Samadikuchaksaraei
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

5.  Immunobiochemical analysis of Paraoxonase1 (anti-oxidant), xanthine oxidase (oxidant) enzymes and lipid profile of cardiac disease patients in Lahore Metropolitan, Pakistan.

Authors:  Zahoor Qadir Samra; Adeela Sana; Sadia Bano; Mariam Farooq; Nadia Dar; Muhammad Amin Athar
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

6.  Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome.

Authors:  György Paragh; Ildikó Seres; Mariann Harangi; Annamária Erdei; Mária Audikovszky; Lóránd Debreczeni; Anna Kovácsay; László Illyés; Gyula Pados
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 7.  Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis.

Authors:  John A Farmer; Joshua Liao
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

8.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes.

Authors:  M C Garin; R W James; P Dussoix; H Blanché; P Passa; P Froguel; J Ruiz
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

9.  Alterations in the high density lipoprotein phenotype and HDL-associated enzymes in subjects with metabolic syndrome.

Authors:  K G Lagos; T D Filippatos; V Tsimihodimos; I F Gazi; C Rizos; A D Tselepis; D P Mikhailidis; Moses S Elisaf
Journal:  Lipids       Date:  2008-10-28       Impact factor: 1.880

Review 10.  LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: role of prooxidants vs. antioxidants.

Authors:  M Aviram; B Fuhrman
Journal:  Mol Cell Biochem       Date:  1998-11       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.